

# Maarten de Wit

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6428712/publications.pdf>

Version: 2024-02-01

115  
papers

15,357  
citations

87401

40  
h-index

25230

113  
g-index

118  
all docs

118  
docs citations

118  
times ranked

11971  
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Correspondence on EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update" by Fallon et al. Annals of the Rheumatic Diseases, 2022, 81, e174-e174.	0.5	14
2	Response to: "Comment on: EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update" by Gossec et al." by Wei et al. Annals of the Rheumatic Diseases, 2022, 81, e139-e139.	0.5	30
3	Response to: "Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis" by Bugatti et al. Annals of the Rheumatic Diseases, 2022, 81, e56-e56.	0.5	1
4	EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. Annals of the Rheumatic Diseases, 2022, 81, 780-785.	0.5	12
5	Identifying potential barriers and solutions to patient partner compensation (payment) in research. Research Involvement and Engagement, 2022, 8, 7.	1.1	14
6	Residual patient-reported burden in 444 patients with psoriatic arthritis in remission or low disease: a cross-sectional analysis. Joint Bone Spine, 2022, , 105372.	0.8	3
7	Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World Evidence. Rheumatology and Therapy, 2022, 9, 803-821.	1.1	11
8	Exploring discordance between Health Literacy Questionnaire scores of people with RMDs and assessment by treating health professionals. Rheumatology, 2022, 62, 52-64.	0.9	3
9	Patient Experienced Symptom State in rheumatoid arthritis: sensitivity to change in disease activity and impact. Rheumatology, 2022, 62, 98-107.	0.9	1
10	Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries. RMD Open, 2022, 8, e002031.	1.8	4
11	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nature Reviews Rheumatology, 2022, 18, 465-479.	3.5	182
12	Comparing the Patient-Reported Physical Function Outcome Measures in a Real-Life International Cohort of Patients With Psoriatic Arthritis. Arthritis Care and Research, 2021, 73, 593-602.	1.5	12
13	Comment on: "It can't be zero!" difficulties in completing patient global assessment in rheumatoid arthritis: a mixed methods study: reply. Rheumatology, 2021, 60, e30-e31.	0.9	0
14	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the Rheumatic Diseases, 2021, 80, 71-87.	0.5	158
15	Addressing Health Literacy Needs in Rheumatology: Which Patient Health Literacy Profiles Need the Attention of Health Professionals?. Arthritis Care and Research, 2021, 73, 100-109.	1.5	19
16	Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group. Annals of the Rheumatic Diseases, 2021, 80, 242-249.	0.5	6
17	Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients. RMD Open, 2021, 7, e001539.	1.8	10
18	What influences patients' opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study. Rheumatology, 2021, 60, 5292-5299.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Experiences and perceptions of patients with psoriatic arthritis participating in a trial of faecal microbiota transplantation: a nested qualitative study. <i>BMJ Open</i> , 2021, 11, e039471.	0.8	8
20	Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2021, , jrheum.201679.	1.0	2
21	Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1158-1167.	0.5	40
22	Patient Perspectives on Outcome Domains of Medication Adherence Trials in Inflammatory Arthritis: An International OMERACT Focus Group Study. <i>Journal of Rheumatology</i> , 2021, 48, 1480-1487.	1.0	0
23	OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 601-606.	1.6	7
24	Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 593-600.	1.6	13
25	Researchersâ€™ perspectives on methodological challenges and outcomes selection in interventional studies targeting medication adherence in rheumatic diseases: an OMERACT-adherence study. <i>BMC Rheumatology</i> , 2021, 5, 26.	0.6	1
26	Psoriatic arthritis. <i>Nature Reviews Disease Primers</i> , 2021, 7, 59.	18.1	113
27	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1108-1112.	1.6	8
28	Improving domain definition and outcome instrument selection: Lessons learned for OMERACT from imaging. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1125-1133.	1.6	18
29	Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. <i>RMD Open</i> , 2021, 7, e001818.	1.8	4
30	Patient and Caregiver Priorities for Medication Adherence in Gout, Osteoporosis, and Rheumatoid Arthritis: Nominal Group Technique. <i>Arthritis Care and Research</i> , 2020, 72, 1410-1419.	1.5	19
31	Determinants of Patientâ€™Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association WithSex in 458 Patients From Fourteen Countries. <i>Arthritis Care and Research</i> , 2020, 72, 1772-1779.	1.5	39
32	Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 12-22.	0.3	7
33	Scope of Outcomes in Trials and Observational Studies of Interventions Targeting Medication Adherence in Rheumatic Conditions: A Systematic Review. <i>Journal of Rheumatology</i> , 2020, 47, 1565-1574.	1.0	15
34	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. <i>RMD Open</i> , 2020, 6, e001374.	1.8	36
35	Cost assessment of health interventions and diseases. <i>RMD Open</i> , 2020, 6, e001287.	1.8	11
36	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1423-1431.	0.5	11

#	ARTICLE	IF	CITATIONS
37	Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 778-786.	0.5	104
38	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 700.1-712.	0.5	609
39	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 760-770.	0.5	205
40	Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1269-1276.	0.5	3
41	Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 744-759.	0.5	167
42	Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 445-452.	0.5	42
43	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.5	1,860
44	Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries. <i>Joint Bone Spine</i> , 2020, 87, 449-454.	0.8	14
45	Health technology assessment: a framework. <i>RMD Open</i> , 2020, 6, e001289.	1.8	17
46	Steps in implementing a health economic evaluation. <i>RMD Open</i> , 2020, 6, e001288.	1.8	5
47	Patient engagement in health technology assessment (HTA) and the regulatory process: what about rheumatology?. <i>RMD Open</i> , 2020, 6, .	1.8	1
48	Patient engagement in health technology assessment (HTA) and the regulatory process: what about rheumatology?. <i>RMD Open</i> , 2020, 6, e001286.	1.8	4
49	Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e109-e109.	0.5	35
50	Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1472-1479.	0.5	7
51	Addressing Challenges in Developing a Core Domain Set in Adherence Interventions in Rheumatology: A Report from the OMERACT-Adherence Group. <i>Journal of Rheumatology</i> , 2019, 46, 1202-1206.	1.0	5
52	Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. <i>Journal of Rheumatology</i> , 2019, 46, 1159-1163.	1.0	11
53	Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019, 46, 1028-1035.	1.0	61
54	Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. <i>Journal of Rheumatology</i> , 2019, 46, 1053-1058.	1.0	8

#	ARTICLE	IF	CITATIONS
55	Be an ambassador for change that you would like to see: a call to action to all stakeholders for co-creation in healthcare and medical research to improve quality of life of people with a neuromuscular disease. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 126.	1.2	10
56	Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2019, 31, 905-915.	1.4	47
57	Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017. <i>Journal of Rheumatology</i> , 2019, 46, 976-980.	1.0	25
58	Practical guidance for patient-centred health research. <i>Lancet</i> , 2019, 393, 1095-1096.	6.3	27
59	Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018. <i>Journal of Rheumatology</i> , 2019, 46, 1355-1359.	1.0	2
60	OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions. <i>Journal of Rheumatology</i> , 2019, 46, 1409-1414.	1.0	14
61	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , 2019, 46, 996-1005.	1.0	36
62	Consensus Building in OMERACT: Recommendations for Use of the Delphi for Core Outcome Set Development. <i>Journal of Rheumatology</i> , 2019, 46, 1041-1046.	1.0	21
63	OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. <i>Journal of Rheumatology</i> , 2019, 46, 1021-1027.	1.0	97
64	Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019, 46, 1014-1020.	1.0	65
65	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , 2019, 46, 990-995.	1.0	43
66	Unique role of rheumatology in establishing collaborative relationships in research. Past, present and future of patient engagement. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 293-296.	0.5	17
67	The Delphi method: more research please. <i>Journal of Clinical Epidemiology</i> , 2019, 106, 136-139.	2.4	71
68	Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 201-208.	0.5	59
69	The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis. <i>Journal of Rheumatology</i> , 2019, 46, 981-989.	1.0	82
70	International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group. <i>Arthritis Care and Research</i> , 2019, 71, 1556-1565.	1.5	43
71	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , 2019, 95, 33-37.	1.0	14
72	Phrasing of the patient global assessment in the rheumatoid arthritis ACR/EULAR remission criteria: an analysis of 967 patients from two databases of early and established rheumatoid arthritis patients. <i>Clinical Rheumatology</i> , 2018, 37, 1503-1510.	1.0	13

#	ARTICLE	IF	CITATIONS
73	Preparing researchers for patient and public involvement in scientific research: Development of a hands-on learning approach through action research. <i>Health Expectations</i> , 2018, 21, 752-763.	1.1	34
74	Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol. <i>Trials</i> , 2018, 19, 204.	0.7	23
75	Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change. <i>Arthritis Care and Research</i> , 2018, 70, 369-378.	1.5	84
76	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.5	484
77	Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study. <i>Arthritis Care and Research</i> , 2018, 70, 1206-1217.	1.5	4
78	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 654-665.	1.6	50
79	Development of a standard form for assessing research grant applications from the perspective of patients. <i>Research Involvement and Engagement</i> , 2018, 4, 27.	1.1	6
80	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 17-25.	1.0	10
81	The eumusc.net standards of care for rheumatoid arthritis: importance and current implementation according to patients and healthcare providers in the Netherlands. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 275-283.	0.4	1
82	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1522-1528.	1.0	93
83	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 673-680.	0.5	194
84	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.5	3,366
85	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 697-700.	1.0	42
86	Emerging Guidelines for Patient Engagement in Research. <i>Value in Health</i> , 2017, 20, 481-486.	0.1	144
87	Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. <i>Rheumatology</i> , 2017, 56, 1573-1578.	0.9	71
88	Determinants of Patient-Physician Discordance in Global Assessment in Psoriatic Arthritis: A Multicenter European Study. <i>Arthritis Care and Research</i> , 2017, 69, 1606-1611.	1.5	58
89	Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1889-1893.	1.0	15
90	Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 1544-1550.	1.0	21

#	ARTICLE	IF	CITATIONS
91	“They Are Talking About Me, but Not with Me”: A Focus Group Study to Explore the Patient Perspective on Interprofessional Team Meetings in Primary Care. <i>Patient</i> , 2017, 10, 429-438.	1.1	26
92	Successful Stepwise Development of Patient Research Partnership: 14 Years’ Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT). <i>Patient</i> , 2017, 10, 141-152.	1.1	41
93	Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. <i>RMD Open</i> , 2016, 2, e000217.	1.8	35
94	Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 965-973.	0.5	179
95	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 952-957.	0.5	258
96	Fatigue in psoriatic arthritis—A cross-sectional study of 246 patients from 13 countries. <i>Joint Bone Spine</i> , 2016, 83, 439-443.	0.8	47
97	Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 490-498.	0.5	98
98	Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP. <i>Journal of Rheumatology</i> , 2016, 43, 187-193.	1.0	46
99	2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 8-13.	0.5	223
100	Development of a Draft Core Set of Domains for Measuring Shared Decision Making in Osteoarthritis: An OMERACT Working Group on Shared Decision Making. <i>Journal of Rheumatology</i> , 2015, 42, 2442-2447.	1.0	22
101	Building Bridges between Researchers and Patient Research Partners: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , 2015, 42, 1021-1026.	1.0	9
102	Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures. <i>Journal of Rheumatology</i> , 2015, 42, 2448-2459.	1.0	21
103	Updating the OMERACT Filter: Implications for Patient-reported Outcomes. <i>Journal of Rheumatology</i> , 2014, 41, 1011-1015.	1.0	54
104	A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1012-1019.	0.5	314
105	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	0.5	1,688
106	Patient Involvement in Outcome Measures for Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, 418.	2.1	34
107	Facilitators to implement standards of care for rheumatoid arthritis and osteoarthritis: the EUMUSC.NET project. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1545-1548.	0.5	9
108	Patient perspective in outcome measures developed by OMERACT. <i>Indian Journal of Rheumatology</i> , 2013, 8, S17-S22.	0.2	8

#	ARTICLE	IF	CITATIONS
109	Involving patient research partners has a significant impact on outcomes research: a responsive evaluation of the international OMERACT conferences. <i>BMJ Open</i> , 2013, 3, e002241.	0.8	145
110	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.5	102
111	Facilitating and inhibiting factors for long-term involvement of patients at outcome conferences – lessons learnt from a decade of collaboration in OMERACT: a qualitative study. <i>BMJ Open</i> , 2013, 3, e003311.	0.8	27
112	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 404-413.	0.5	657
113	What have we learned from a decade of patient involvement in OMERACT and its effect on trial outcome assessments?. <i>Trials</i> , 2011, 12, .	0.7	2
114	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 631-637.	0.5	1,711
115	Patients and professionals as research partners: Challenges, practicalities, and benefits. <i>Arthritis and Rheumatism</i> , 2006, 55, 676-680.	6.7	214